References
- Anzola M, Cuevas N, Lopez-Martinez M, et al (2003). Frequent loss of p53 codon 72 Pro variant in hepatitis C virus-positive carriers with hepatocellular carcinoma. Cancer Lett, 193, 199-205. https://doi.org/10.1016/S0304-3835(03)00046-6
- Bridges JF, Joy SM, Gallego G, et al (2011). Needs for hepatocellular carcinoma control policy in the Asia-Pacific region. Asian Pac J Cancer Prev, 12, 2585-91.
- Chen X, Liu F, Li B, et al (2011). p53 codon 72 polymorphism and liver cancer susceptibility: a meta-analysis of epidemiologic studies. World J Gastroenterol, 17, 1211-8. https://doi.org/10.3748/wjg.v17.i9.1211
- DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88. https://doi.org/10.1016/0197-2456(86)90046-2
- Di Vuolo V, Buonaguro L, Izzo F, et al (2011). TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients. Infect Agent Cancer, 6, 13. https://doi.org/10.1186/1750-9378-6-13
- Dumont P, Leu JI, Della Pietra AC, 3rd, et al (2003). The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet, 33, 357-65. https://doi.org/10.1038/ng1093
- Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34. https://doi.org/10.1136/bmj.315.7109.629
- El-Serag HB (2011). Hepatocellular carcinoma. N Engl J Med, 365, 1118-27. https://doi.org/10.1056/NEJMra1001683
- Ezzikouri S, El Feydi AE, Chafik A, et al (2007). The Pro variant of the p53 codon 72 polymorphism is associated with hepatocellular carcinoma in Moroccan population. Hepatol Res, 37, 748-54. https://doi.org/10.1111/j.1872-034X.2007.00126.x
- Ezzikouri S, Essaid El Feydi A, Afifi R, et al (2011). Impact of TP53 codon 72 and MDM2 promoter 309 allelic dosage in a Moroccan population with hepatocellular carcinoma. Int J Biol Markers, 26, 229-33.
- Feng GS (2012). Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell, 21, 150-4. https://doi.org/10.1016/j.ccr.2012.01.001
- Forner A, Llovet JM, Bruix J (2012). Hepatocellular carcinoma. Lancet, 379, 1245-55. https://doi.org/10.1016/S0140-6736(11)61347-0
- Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60. https://doi.org/10.1136/bmj.327.7414.557
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Kimman M, Norman R, Jan S, et al (2012). The Burden of Cancer in Member Countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev, 13, 411-20. https://doi.org/10.7314/APJCP.2012.13.2.411
- Leveri M, Gritti C, Rossi L, et al (2004). Codon 72 polymorphism of P53 gene does not affect the risk of cirrhosis and hepatocarcinoma in HCV-infected patients. Cancer Lett, 208, 75-9. https://doi.org/10.1016/j.canlet.2004.02.016
- Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
- Pawlik P, Mostowska A, Lianeri M, et al (2012). Folate and choline metabolism gene variants in relation to ovarian cancer risk in the Polish population. Mol Biol Rep, 39, 5553-60. https://doi.org/10.1007/s11033-011-1359-0
- Peng T, Yan LN, Liu ZM, et al (2004). Significant association between p53 codon 72 Pro polymorphism and hepatocellular carcinoma risk in Guangxi. Chin J Surg, 42, 313-4. [Article in Chinese]
- Reinhardt HC, Schumacher B (2012). The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet, 28, 128-36. https://doi.org/10.1016/j.tig.2011.12.002
- Riley T, Sontag E, Chen P, et al (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol, 9, 402-12. https://doi.org/10.1038/nrm2395
- Sia D, Villanueva A (2011). Signaling pathways in hepatocellular carcinoma. Oncology, 81, 18-23. https://doi.org/10.1159/000333254
- Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology. JAMA, 283, 2008. https://doi.org/10.1001/jama.283.15.2008
- Stuck AE, Rubenstein LZ, Wieland D (1998). Bias in metaanalysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ, 316, 469. https://doi.org/10.1136/bmj.316.7129.469
- Sumbul AT, Akkiz H, Bayram S, et al (2012). p53 codon 72 polymorphism is associated with susceptibility to hepatocellular carcinoma in the Turkish population: a casecontrol study. Mol Biol Rep, 39, 1639-47. https://doi.org/10.1007/s11033-011-0903-2
- Whibley C, Pharoah PD, Hollstein M (2009). p53 polymorphisms: cancer implications. Nat Rev Cancer, 9, 95-107. https://doi.org/10.1038/nrc2584
- Xu Y, Liu L, Liu J, et al (2011). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer, 128, 412-7. https://doi.org/10.1002/ijc.25342
- Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6. https://doi.org/10.1093/carcin/bgn090
- Yu MW, Yang SY, Chiu YH, et al (1999). A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology, 29, 697-702. https://doi.org/10.1002/hep.510290330
- Zhang L, Liu W, Hao Q, et al (2012). Folate intake and methylenetetrahydrofolate reductase gene polymorphisms as predictive and prognostic biomarkers for ovarian cancer risk. Int J Mol Sci, 13, 4009-20. https://doi.org/10.3390/ijms13044009
- Zhu ZZ, Cong WM, Liu SF, et al (2005). [p53 gene codon 72 polymorphism and genetic susceptibility to hepatocellular carcinoma in Chinese population]. Zhonghua Yi Xue Za Zhi, 85, 76-9. [Article in Chinese]
- Zhu ZZ, Cong WM, Liu SF, et al (2005). Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol, 11, 289-92. https://doi.org/10.3748/wjg.v11.i2.289
- Zhu ZZ, Cong WM, Liu SF, et al (2005). A p53 polymorphism modifies the risk of hepatocellular carcinoma among noncarriers but not carriers of chronic hepatitis B virus infection. Cancer Lett, 229, 77-83. https://doi.org/10.1016/j.canlet.2005.04.014
- Zhu ZZ, Cong WM, Zhu GS, et al (2005). [Association of p53 codon 72 polymorphism with genetic susceptibility to hepatocellular carcinoma in Chinese population]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi, 22, 632-5.[Article in Chinese]
Cited by
- Crosstalk between EGFR and p53 in Hepatocellular Carcinoma vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8069
- Association of rs1042522 Polymorphism with Increased Risk of Prostate Adenocarcinoma in the Pakistani Population and its HuGE Review vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3973
- Effect of vascular endothelial growth factor siRNA and wild-type p53 co-expressing plasmid in MDA-MB-231 cells vol.13, pp.1, 2015, https://doi.org/10.3892/mmr.2015.4571
- Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis vol.97, pp.1469-5073, 2015, https://doi.org/10.1017/S0016672315000075